Manta Cares, a digital health company founded by cancer survivor Samira Daswani, has announced a multi-year collaboration with Gilead Sciences to support patients navigating metastatic cancer. The collaboration includes nationwide rollout of Manta’s personalized cancer navigation tools, real-world implementation pilots, community outreach, and ongoing research.
For breast cancer patients specifically, the partnership addresses a persistent gap: the space between clinical appointments where decisions are made, stress builds, and support is often absent. Manta’s platform helps patients track symptoms, medications, and appointments, organize questions for care teams, and bring structure to a fragmented experience. Early feedback from real-world pilots found the platform helped patients feel more confident and prepared for conversations with their care teams.
“When you’re living with cancer, the support you need doesn’t wait for your next appointment,” said Manta Cares founder and CEO Samira Daswani. “Gilead’s early support helped us move faster, reach further, and ensure our tools met patients where they are – between visits and in daily life, where decisions are made and stress builds.”
Gilead is also supporting independent researcher-led studies evaluating how patients and providers adopt the Manta platform in real-world settings. Findings have already been featured in abstracts and posters at ASCO 2025 and ASCO QCS 2025.
“This is about more than technology,” said Darren Tayama, MD, VP of U.S. Medical Affairs, Oncology at Gilead. “It’s about trust, impact, and meeting patients in the real world.”
Manta Cares is backed by Pear VC, Sozo Ventures, and 1843 Capital, and works with four of the top 15 pharmaceutical manufacturers. The collaboration is part of Gilead’s Community Cancer Collective initiative.
